Richard Walters, OD
Optometrist · Alexandria, LANPI 1881655082
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,821 of the $3,488 with a category attached, or 80.9%. 23 manufacturers reported payments, led by Alcon at 34.0% of the total. Reporting peaked in 2019 at $1,268 and has fallen 95.6% since, to $55 in 2025.
Across 69 payments — averaging $50.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Sight Sciences, Inc.$377
- Ivantis, Inc$306
- AbbVie$274
- Johnson & Johnson Surgical Vision, Inc.$223
- Glaukos Corporation$222
- plus $901 from 17 others
Across 13 payments — averaging $1368.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$18K
What the payments were for
- Travel & lodging$66619%
- Food & beverage$2,82181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 13 | $1,185 |
| Sight Sciences, Inc. | 7 | $377 |
| Ivantis, Inc | 4 | $306 |
| AbbVie(2 entities) | 5 | $274 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $223 |
| Glaukos Corporation | 7 | $222 |
| Rxsight Inc | 4 | $190 |
| Aerie Pharmaceuticals, Inc. | 2 | $143 |
| Sun Pharmaceutical Industries Inc. | 5 | $111 |
| Optos, Inc. | 1 | $98 |
| Coopervision Inc. | 2 | $61 |
| Tarsus Pharmaceuticals, Inc. | 1 | $58 |
| Oyster Point Pharma, Inc. | 2 | $33 |
| Bausch & Lomb Americas Inc. | 2 | $31 |
| Biotissue Holdings Inc. | 1 | $28 |
| Shire North American Group Inc | 1 | $25 |
| Ocular Therapeutix, Inc. | 1 | $24 |
| Harrow Eye, LLC | 1 | $20 |
| Rayner Intraocular Lenses Limited | 1 | $18 |
| Tearlab Corp | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Novartis | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AcrySof$381
- Hydrus Microstent$163
- Rhopressa$125
- Rocklatan$125
- DAILIES$125
- Tecnis IOL$120
- TearCare SmartLid$120
- TEARCARE(TM) (2.2) SYSTEM KIT$120
- XEN$110
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$108
- Hydrus$108
- TEARCARE SYSTEM$104
- LUMIGAN$101
How this compares
$3,488 in reported general payments places this provider in the 75th percentile of 500 optometrist providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CombiganBrimonidine Tartrate/Timolol | 26 | $9,207 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 26 | $5,601 |
| Latanoprost | 273 | $3,241 |
| Bromfenac Sodium | 12 | $1,217 |
| Timolol Maleate | 55 | $534 |
| Brimonidine Tartrate | 25 | $323 |
| Dorzolamide Hcl | 14 | $275 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 11 | $211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan | $274 | $9,20726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 500 optometrist providers in Louisiana.
Other optometrist in Alexandria
- Brett BennettAlexandria$6K
- Phillip CarneyAlexandria$6K
- Pamela TheriotShreveport$207K
- Joshua DavidsonGonzales$189K
- Jeffrey WilhiteMarrero$86K
- Christopher WrotenHammond$59K
- James LamarNew Orleans$45K
- John McCallLogansport$32K
- Robert KellyMarrero$26K
- Shane FontenotJennings$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.